Insulin Receptor Substrate-2 (Irs2) in Endothelial Cells Plays a Crucial Role in Insulin

[1]  P. Leung,et al.  The role of renin-angiotensin system in cellular differentiation: Implications in pancreatic islet cell development and islet transplantation , 2013, Molecular and Cellular Endocrinology.

[2]  Alvin C. Powers,et al.  Pancreatic Islet Vasculature Adapts to Insulin Resistance Through Dilation and Not Angiogenesis , 2013, Diabetes.

[3]  F. Larsen,et al.  Inorganic nitrite stimulates pancreatic islet blood flow and insulin secretion. , 2012, Free radical biology & medicine.

[4]  P. Carlsson,et al.  A Low-Oxygenated Subpopulation of Pancreatic Islets Constitutes a Functional Reserve of Endocrine Cells , 2011, Diabetes.

[5]  T. Kodama,et al.  Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. , 2011, Cell metabolism.

[6]  A. Attie,et al.  The role of blood vessels, endothelial cells, and vascular pericytes in insulin secretion and peripheral insulin action. , 2010, Endocrine reviews.

[7]  G. Reaven.  HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not? , 2009, Diabetes & vascular disease research.

[8]  Y. Aizawa,et al.  Improved Early-Phase Insulin Response after Candesartan Treatment in Hypertensive Patients with Impaired Glucose Tolerance , 2008, Clinical and experimental hypertension.

[9]  E. Bertin,et al.  Follow-up of GK rats during prediabetes highlights increased insulin action and fat deposition despite low insulin secretion. , 2008, American journal of physiology. Endocrinology and metabolism.

[10]  P. Leung.  The physiology of a local renin–angiotensin system in the pancreas , 2007, The Journal of physiology.

[11]  M. Welsh,et al.  Glucose intolerance and reduced islet blood flow in transgenic mice expressing the FRK tyrosine kinase under the control of the rat insulin promoter. , 2007, American journal of physiology. Endocrinology and metabolism.

[12]  H. Aburatani,et al.  Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. , 2007, The Journal of clinical investigation.

[13]  Å. Sjöholm,et al.  Vasoactive drugs enhance pancreatic islet blood flow, augment insulin secretion and improve glucose tolerance in female rats. , 2007, Clinical science.

[14]  Min Zhang,et al.  Total insulin and IGF-I resistance in pancreatic β cells causes overt diabetes , 2006, Nature Genetics.

[15]  H Joseph Goren,et al.  Role of insulin in glucose-stimulated insulin secretion in beta cells. , 2005, Current diabetes reviews.

[16]  M. Iida,et al.  Nateglinide, a non-sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats. , 2005, European journal of pharmacology.

[17]  J. Holst,et al.  Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. , 2005, Diabetes.

[18]  C. Reid,et al.  Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. , 2005, Journal of hypertension.

[19]  T. Noda,et al.  Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. , 2004, The Journal of clinical investigation.

[20]  Merlin C. Thomas,et al.  Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. , 2004, Diabetes.

[21]  P. Brunetti,et al.  ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with Type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension , 1991, Diabetologia.

[22]  K. Kosaka,et al.  Risk factors for worsening to diabetes in subjects with impaired glucose tolerance , 2004, Diabetologia.

[23]  S. Aizawa,et al.  Kadowaki and Tetsu Yamaguchi Lack of Insulin Receptor Substrate-2 Causes Progressive Neointima Formation in Lack of Insulin Receptor Substrate-2 Causes Progressive Neointima Formation in Response to Vessel Injury , 2022 .

[24]  Samy I McFarlane,et al.  Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. , 2003, The American journal of cardiology.

[25]  D. Melton,et al.  Role of VEGF-A in Vascularization of Pancreatic Islets , 2003, Current Biology.

[26]  A. Zanchetti,et al.  Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? , 2002, Journal of hypertension.

[27]  R. Bergman,et al.  The evolution of β‐cell dysfunction and insulin resistance in type 2 diabetes , 2002, European journal of clinical investigation.

[28]  T. Kadowaki,et al.  Insights into insulin resistance and type 2 diabetes from knockout mouse models. , 2000, The Journal of clinical investigation.

[29]  P. Raskin,et al.  A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. , 1999, American journal of hypertension.

[30]  S. Kahn,et al.  Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. , 1999, Diabetes.

[31]  C. Berne,et al.  Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats , 1998, Diabetologia.

[32]  S. Jacob,et al.  Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle. , 1996, Metabolism: clinical and experimental.

[33]  C. Yokota,et al.  Normalization of insulin resistance in non-obese essential hypertension by cilazapril treatment. , 1995, Clinical and experimental hypertension.

[34]  A. Golay,et al.  Insulin Sensitivity in Obese Hypertensive Dyslipidemic Patients Treated with Enalapril or Atenolol , 1995, Journal of cardiovascular pharmacology.

[35]  T. Rosenthal,et al.  The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM. , 1995, American journal of hypertension.

[36]  L. Jansson.  The regulation of pancreatic islet blood flow. , 1994, Diabetes/metabolism reviews.

[37]  L. Lind,et al.  Electrolyte changes and metabolic effects of lisinopril/bendrofluazide treatment. Results from a randomized, double-blind study with parallel groups. , 1994, American journal of hypertension.

[38]  W. Sheu,et al.  Improvement in metabolic risk factors for coronary heart disease associated with cilazapril treatment. , 1992, American journal of hypertension.

[39]  C. Palombo,et al.  Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension. , 1992, Hypertension.

[40]  G. Paolisso,et al.  ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. , 1992, Journal of human hypertension.

[41]  R. Gans,et al.  The effect of angiotensin‐l converting enzyme inhibition on insulin action in healthy volunteers , 1991, European journal of clinical investigation.

[42]  C. Berne,et al.  A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. , 1989, The New England journal of medicine.

[43]  I. Beckingham,et al.  Islet blood flow following insulin administration. , 1989, Journal of anatomy.

[44]  K. Rett,et al.  Captopril enhances insulin responsiveness of forearm muscle tissue in non‐insulin‐dependent diabetes mellitus , 1987, European journal of clinical investigation.

[45]  L. Jansson,et al.  A rapid method of visualizing the pancreatic islets for studies of islet capillary blood flow using non-radioactive microspheres. , 1981, Acta physiologica Scandinavica.